Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

That could be through habit-forming actions to help improve your daily movement, or by achieving your weight loss goals.

Meanwhile, those in the placebo group gained between 1.9% and 2.3%. Novo also tested an oral version of amycretin last year, ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Join a suite of experts from across the industry Jan. 29 for a free online event examining the opportunities and challenges ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are "concerned that the current regulations allow some patients to ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...